Project Title: Proof of concept; an open label pilot study to determine the efficacy and tolerability of a treated gliadincontaining product in asymptomatic subjects with coeliac disease.
Principle investigators:Dr R. Grant, Prof B. Jones, Dr J. Ashton.
Coeliac disease is an inflammatory disorder affecting the upper small intestine and is usually caused by an allergic response to ingestion of gluten found in wheat, rye and barley causing inflammation of the small intestine often preventing efficient absorption of important nutrients from food. This study is in the process of testing whether a new process for removing toxic gluten proteins is affective. If successful, the treatment process should enable patients with coeliac disease to again eat wheat containing products provided they have been detoxified in this way.
Project title: Randomised comparative study of FOLFOX6m plus SIR-Spheres(r) versus FLOFOX6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma.
Sponsor: Sirtex
Principle investigators: Dr Gavin Marx, Dr Joseph Rutovitz
No of patients and durations: 10 patients, 18 months
Stage: Site initiation meeting - June 21 2007
Colorectal cancer is the 3rd most common cancer in the western worlds. 70% of all patients will develop mtastases in the liver.The outlook for such patients is poor with conventional treatments. Selective internal radiation Therapy (SIRT), using SIR Spheres is a method of delivering therapeutic radiation to hepatic tumours while sparing the normal liver cells. This internationalstudy will assess the effect of a single implant of SIR-Spheres to a standard regimen of FOLFOX.
Project Title: IBIS-II DCIS
Sponsor: The Australian New Zealand Breast Cancer Trials Group - Coordinates and holds overall responsibility for the conduct of this trial in Australia and New Zealand.
Principle investigators: Dr Gavin Marx
No of Patients and Duration: up to 50, 2 yrs
Stage: Site initiation meeting - June 2007
This study is looking at the possibility of preventing the return of breast cancer in women who have been diagnosed with ductal carcinoma in situ (DCIS) of the breast. The study will involve 4,000 women from around the world, who are postmenopausal and have been diagnosed with DCIS within the last six months. The drugs being tested in the study, tamoxifen and anastrozole, are provided by the pharmaceutical company AstraZeneca at no cost to study participants. In recent clinical trials women with DCIS have been given tamoxifen, and results show a reduction in the number of women whose DCIS progressed into invasive breast cancer. However, further research is needed to determine the particular group of women with DCIS who will benefit from taking tamoxifen.The purpose of the IBIS II DCIS study is to find out whether anastrozole is as effective or better than tamoxifen in preventing the development of breast cancer .The study will also compare the effects (good and bad) of tamoxifen and anastrozole.
Clinical Trials 
